Cargando…
Epigenetic Modifications in Alzheimer’s Neuropathology and Therapeutics
Transcriptional activation is a highly synchronized process in eukaryotes that requires a series of cis- and trans-acting elements at promoter regions. Epigenetic modifications, such as chromatin remodeling, histone acetylation/deacetylation, and methylation, have frequently been studied with regard...
Autores principales: | Esposito, Michelle, Sherr, Goldie Libby |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524410/ https://www.ncbi.nlm.nih.gov/pubmed/31133796 http://dx.doi.org/10.3389/fnins.2019.00476 |
Ejemplares similares
-
The Contribution and Therapeutic Potential of Epigenetic Modifications in Alzheimer’s Disease
por: Wood, Ian C.
Publicado: (2018) -
Inhibition of Amyloid-Beta Production, Associated Neuroinflammation, and Histone Deacetylase 2-Mediated Epigenetic Modifications Prevent Neuropathology in Alzheimer’s Disease in vitro Model
por: Atluri, Venkata Subba Rao, et al.
Publicado: (2020) -
The Molecular and Neuropathological Consequences of Genetic Risk for Alzheimer's Dementia
por: Tasaki, Shinya, et al.
Publicado: (2018) -
Accumulation of unacetylatable Snf2p at the INO1 promoter is detrimental to remodeler recycling supply for CUP1 induction
por: Esposito, Michelle, et al.
Publicado: (2020) -
Lipids and lipoproteins may play a role in the neuropathology of Alzheimer’s disease
por: Akyol, Omer, et al.
Publicado: (2023)